pharmaphorum

OCTOBER 12, 2022

Overall, the aim is to improve the efficiency of drug discovery by identifying genetic variants that contribute to human disease in omics data – a broad category that includes DNA profiles, gene transcripts, and protein expression.

Genome 64

Genome Genomics DNA Drugs 64

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies. Here are four life sciences trends to look out for in 2023.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264

Research Gene Gene Therapy Genome 264

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. Biotech and AI companies founded by purely tech professionals often opt to bring in pharma executives with insider knowledge further down the line.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

XTalks

DECEMBER 20, 2023

Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. Cambridge is a focal point for many pharmaceutical companies working in this therapeutic area. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 77

Marketing Gene Silencing Gene Drugs 77

The Pharma Data

OCTOBER 20, 2020

MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. Targeted therapies, genetic sequencing, gene editing, immunotherapies. Ochsner Health and LSU Health Shreveport have offered themselves as additional trial sites to increase patient access to studies. .

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Trials 52

pharmaphorum

APRIL 26, 2022

Research into the area is being made possible through advancements in technology, such as being able to sequence genes at scale, allowing researchers to gain more detailed genetic data on the microbiome.

Containment 108

Containment Development Production Immune Response 108

Delveinsight

AUGUST 6, 2020

Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one. The hATTR diagnosis is mainly dependent on symptoms and can be confirmed via performing tissue biopsies, genetic testing, and imaging studies.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. With the advancement in technology, today diagnostics testing such as neurological examination, brain scans, genetic screening, and other tests are available to examine the occurrence of Neurological Conditions.

Marketing 98

Marketing Genetics Development Clinical Development 98

Drug Discovery World

DECEMBER 14, 2023

Glasgow is also an important centre for the MRC National Mouse Genetics Network, which aims to integrate mouse genetics, cell and tissue systems and deep phenotyping with human data, and develop preclinical platforms that facilitate the rapid translation of mouse data into the clinic.

Drugs 75

Drugs Life Science Research Scientist 75

Drug Discovery World

FEBRUARY 6, 2024

Biopharma and biotech companies without these capabilities are keen to harness these technologies and the number of strategic partnerships with such companies is accelerating at an unprecedented rate. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

XTalks

DECEMBER 20, 2023

“In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Smith joined SpringWorks at the company’s inception in 2017 and was a founding member of the management team.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

OCTOBER 26, 2022

And the company lives its commitment to patient centricity through all its operations, Chiesi explained. For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Caring for a global community. About Chiesi Group.

Development 82

Development Trials Marketing Life Science 82

pharmaphorum

NOVEMBER 27, 2022

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs.

Genome 90

Genome Genomics Genetics Medicine 90

World of DTC Marketing

JANUARY 31, 2021

The venture capitalists funding them are looking for a big payday when a pharma company acquires them. I have been recruited by these companies who promise huge payouts when they are acquired if their drug shows promise in clinical trials. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1

In-Vivo 187

In-Vivo Generic Drugs Gene Therapy Drugs 187

pharmaphorum

JANUARY 10, 2022

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. This not only allowed Pfizer to establish a COVID-19 vaccine but the company also recently announced that it had begun a study testing an mRNA flu vaccine.

RNA 105

RNA Vaccination Vaccine Pharma Companies 105

pharmaphorum

DECEMBER 6, 2022

A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. There are also hopes that clues could be found as to what risk factors are involved in the development of the most difficult to understand diseases. Hope for patients.

Genome Project 93

Genome Project Research Genome Genomics 93

Drug Discovery World

APRIL 27, 2023

Dr Mansley also comments that the multitude of biotech and pharma companies in the Greater Boston region means that people regularly move organisations. She said: “When one of our customers leaves a company and moves to a new one up the street, they often get in touch with us, which helps us grow new business.

Life Science 52

Life Science Drugs Research Gene Splicing 52

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% We are seeing the change from traditional biopharmaceuticals to cell and gene therapies.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

SEPTEMBER 1, 2020

This knowledge of genetics and the underlying cause of many diseases, including cancer, has resulted in powerful new drugs. In cancer, the pharma industry has begun producing immunotherapies, which do not act directly against the disease but instead enlist the immune system to fight against malignant tissues.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

XTalks

OCTOBER 15, 2021

The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctors 105

Drug Discovery World

NOVEMBER 15, 2022

Even as methods in DNA synthesis continue to advance, scientists’ reliance on third-party companies for synthesising DNA creates a bottleneck, impeding research timelines. . “If If you want to order gene-length sequences, rather than short oligos for PCR, the waiting times are around two or three weeks at least.

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

DECEMBER 22, 2021

RNA therapeutics hold promise as powerful treatments for diseases, including those that are genetic-based. The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. RNA Therapeutics.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. Genetic counseling and other symptomatic treatment also help. Argininosuccinic aciduria is a rare disease that is genetically inherited.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

Delveinsight

DECEMBER 2, 2020

Some of the most common factors include: Genes – Genes are considered to play a small role in Rheumatoid Arthritis. Smoking – Cigarette smoking, coupled with the genetic factor, can increase the risk of developing Rheumatoid Arthritis. What are the Risk Factors for Developing Rheumatoid Arthritis?

Marketing 60

Marketing Hormones Antibody Development 60

The Pharma Data

DECEMBER 30, 2020

It is a strong potential player in the gene therapy space. Its lead candidate is AMT-061, an AAV5-based gene therapy being evaluated for severe and moderately severe hemophilia B in the Phase III HOPE-B study. billion, Regenxbio is also a gene therapy company. UniQure has a market cap of $2.1 With a market cap of $1.6

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

Pharmaceutical Technology

MARCH 20, 2023

Pharma companies and world health stand to benefit from new technologies, but it’s a tough time to be an investor – and an even tougher one for firms seeking investment. Research – and money – going into even more advanced gene therapies is ramping up. Further rate hikes could be on the way this year. Source: GlobalData.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130